Drug library screening of 294 FDA-approved or clinical trial-tested compounds in KRAS-independent and -dependent cancer cell lines identified AT7519, a CDK 1, 2, 7, and 9 inhibitor as a potent inhibitor of the viability of KRAS-dependent cells. This evidence concerns the gene KRAS and cancer.